Project Oncology®

177 Folgen

1. Navigating a Positive MCED Test and Negative Diagnostic Workup: Real-World Data

   Vom: 28.3.2025
2. AML Care: Examining the Efficacy and Safety of a Triplet Combination Therapy

   Vom: 14.3.2025
3. Diagnosis and Management of Metastatic PDAC

   Vom: 13.1.2025
4. Chemotherapy Strategies for Metastatic PDAC

   Vom: 13.1.2025
5. Predictive Models for CAR T-Cell Therapy: Personalizing R/R LBCL Care

   Vom: 8.1.2025
6. Sacituzumab Govitecan for mTNBC: A Review of Real-World Efficacy and Safety Data

   Vom: 7.1.2025
7. Mastering CAR-T Cell Therapy in R/R Large B-Cell Lymphoma: Adverse Event Management

   Vom: 7.1.2025
8. Preventing Adverse Events in CAR T-Cell Therapy: The Evolution of Safety Protocols

   Vom: 2.1.2025
9. Treating Second-Line NSCLC: The Efficacy of ADCs Targeting Predictive Biomarkers

   Vom: 31.12.2024
10. Treating NSCLC with Durvalumab, Chemotherapy, and Novel Agents: Preliminary Results

    Vom: 23.12.2024
11. Evaluating Valemetostat and Dato-DXd for NSCLC: An Upcoming Trial

    Vom: 23.12.2024
12. Dato-DxD for NSCLC: A Review of Final Overall Survival Data from TROPION-Lung01

    Vom: 23.12.2024
13. Analyzing Dato-DXd for Non-Squamous NSCLC with Brain Metastases

    Vom: 23.12.2024
14. Understanding Heparin Resistance: Underlying Mechanisms and Alternative Treatment Options

    Vom: 16.12.2024
15. The Future of ITP Care: Exploring New Treatments

    Vom: 16.12.2024
16. Understanding iMCD Through RNA Sequencing

    Vom: 16.12.2024
17. NSCLC Care: Predicting Response to Dato-DXd with a TROP2 Biomarker

    Vom: 13.12.2024
18. Diagnosing Castleman Disease: Key Considerations

    Vom: 10.12.2024
19. Improving Diagnosis of Castleman Disease: The Key Role of Stromal Cells

    Vom: 9.12.2024
20. Poster Pearl: Treating ER+/HER2- mBC with Elacestrant and Endocrine Therapy

    Vom: 27.11.2024